Clinical trials: Hypertension, Essential
Hypertension,Essential
Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension
The purpose of this study is to determine the optimal dose of AD-209 in patients with Essential Hypertension.
- Trial name
- NCT04218552
- Testing
- AD209, Amlodipine low, Amlodipine high
- Where
- South Korea
- Volunteers
- 176 people
- Sponsor
- Addpharma Inc.
Essential Hypertension
Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Early Morning Blood Pressure and Central Arterial Pressure
The purpose of this study is to compare nifedipine controlled-release (CR) tablets (Xin Ran) with nifedipine controlled-release tablets (Adalat）in the treatment of Early Morning Blood Pressure and Central Arterial Pressure.
- Trial name
- NCT02357615
- Testing
- nifedipine CR tablets (Xin Ran), Adalat
- Where
- China
- Volunteers
- 244 people
- Sponsor
- Shanghai Shyndec Pharmaceutical Co., Ltd.
Essential Hypertension, Dyslipidemia
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia
The purpose of this study is to evaluate the efficacy and safety of combination of Fimasartan/Rosuvastatin in comparison to each component administered alone in patients with essential hypertension and dyslipidemia.
- Trial name
- NCT02166814
- Testing
- Fimasartan and Rosuvastatin, Fimasartan, Rosuvastatin
- Where
- 26 sites in South Korea
- Volunteers
- 140 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Diabetic Kidney Disease, Proteinuria
An Observation Study to Evaluate the Renoprotective Effect of Fimasartan in Patients With DKD and Proteinuria
This study aims to observe changes in various indicators of renal function, such as proteinuria at different time points: short-term (Week 8), 6 months (Week 26), and a year (Week 52), in patients with DKD and hypertension, who…
- Conditions
- Diabetic Kidney Disease, Proteinuria, Hypertension,Essential
- Trial name
- FINALE (NCT05086549)
- Where
- South Korea
- Volunteers
- 360 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
A Study to Evaluate the Pharmacokinetic, Pharmacodynamic Characteristics and the Safety After Administration by Doses of BR1400-1, BR1400-2, BR1400-3 in Healthy Adult Volunteers
The purpose of this clinical study is to evaluate the pharmacokinetic, pharmacodynamic characteristics and the safety after administration by doses of "BR1400-1", "BR1400-2", "BR1400-3" in healthy volunteers
- Trial name
- NCT06889064
- Testing
- BR1400-1, BR1400-2, BR1400-3
- Where
- South Korea
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
CKD-828(80/2.5mg) Pharmacokinetic Study_2nd
The purpose of this study is to evaluate the pharmacokinetic characteristics of CKD-828(Fixed Dose Combination Tablet; Telmisartan and S-Amlodipine) in healthy volunteer.
- Trial name
- NCT01352689
- Testing
- CKD-828(FDC), Combination Therapy
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Essential Hypertension
Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Blocker (ARB) Plus Amlodipine
This study will assess the efficacy and safety of the single pill combination of Aliskiren and Amlodipine in patients with moderate hypertension not adequately responding to a single pill combination of Olmesartan and Amlodipine.
- Trial name
- AWESOME (NCT01113047)
- Testing
- Aliskiren/Amlodipine and Aliskiren/Amlodipine/HCTZ
- Where
- Germany
- Volunteers
- 347 people
- Sponsor
- Novartis
Hypertension,Essential
A Study to Evaluate the Efficacy and Safety of AD-223
The purpose of this study is to evaluate the efficacy and safety of AD-223
- Trial name
- NCT06052748
- Testing
- AD-223A, AD-223B, AD-223C
- Where
- South Korea
- Volunteers
- 502 people
- Sponsor
- Addpharma Inc.
Hypertension
Safety, Tolerability, and Efficacy of Once Daily Amlodipine/Valsartan 5/80 as Compared to Amlodipine/Valsartan 5/40 or to Amlodipine 5 mg Monotherapy in Patients 65 Years of Age and Older With Essential Hypertension
To characterize the safety, tolerability, and efficacy profile of amlodipine/valsartan 5/80 mg as compared to amlodipine/valsartan 5/40 mg (with optional titration to 5/80 mg) and amlodipine 5 mg monotherapy in elderly patients…
- Trial name
- NCT00699192
- Testing
- Amlodipine 5 mg, Valsartan 80 mg, Valsartan 40 mg
- Where
- 18 sites in Czechia, Finland and 8 more
- Volunteers
- 965 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension,Essential
An OS to Evaluate Effectiveness and Safety of Fixed-dose Combinations of FMS/AML or FMS/AML/HCTZ
The main purpose of this observation study is to collect data on the effects and side effects for 12 weeks of the medication administration of the single-pill combinations, which are fimasartan/amlodipine or…
- Trial name
- NCT05413057
- Where
- South Korea
- Volunteers
- 20,000 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
Efficacy and Safety of LCZ696 Compared to Placebo in Patients With Essential Hypertension
This study is a phase 2 study in patients with essential hypertension.
- Trial name
- NCT01193101
- Testing
- LCZ696
- Where
- 34 sites in China, Japan and 3 more
- Volunteers
- 389 people
- Sponsor
- Novartis Pharmaceuticals
Essential Hypertension
The Prevalence of Sympathetic Overactivity in Primary Hypertensive Patients.
The purpose of this NIS is to assess the prevalence of sympathetic overactivity in patients with newly diagnosed essential hypertension.
- Trial name
- SORT (NCT01295021)
- Where
- 97 sites in India
- Volunteers
- 1,514 people
- Sponsor
- AstraZeneca
Essential Hypertension
Clinical Efficacy and Safety Evaluation of Irbesartan High and Amlodipine Combined Therapy in Essential Hypertension Patients
The purpose of this study is to evaluate efficacy and safety of Irbesartan and Amlodipine combined therapy in patients with essential hypertension inadequately controlled on Irbesartan monotherapy
- Trial name
- NCT05475665
- Testing
- Irbesartan/Amlodipine, Irbesartan
- Where
- South Korea
- Volunteers
- 157 people
- Sponsor
- Handok Inc.
Hypertension
A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure
The purpose of this study is to evaluate the safety and blood pressure lowering effect of different doses of PF-00489791 in patients with mild to moderate high blood pressure
- Trial name
- NCT00422461
- Testing
- PF-00489791
- Where
- 20 sites in United States
- Volunteers
- 135 people
- Sponsor
- Pfizer
Hypertension
Hyzaar Asia HEAALTH (0954A-950)
The objective of the study is to estimate the percentage of patients who reach blood pressure goal after 8 weeks of treatment with losartan/HCTZ combination.
- Trial name
- NCT00354991
- Testing
- losartan potassium (+) hydrochlorothiazide
- Volunteers
- 437 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypertension
Safety, Tolerability and Efficacy of Micardis® in Patients With Essential Hypertension
This post-marketing surveillance study was designed to supplement under conditions of normal clinical practice the data on the safety, tolerability and efficacy of Micardis® collected during the clinical studies.
- Trial name
- NCT02176850
- Testing
- Micardis®
- Volunteers
- 19,870 people
- Sponsor
- Boehringer Ingelheim
Hypertension, Essential
A Study to Evaluate the Efficacy and Safety of AD-209
The purpose of this study is to evaluate the efficacy and safety of AD-209
- Trial name
- NCT05631990
- Testing
- AD-209, AD-209-1A, AD-209-1B
- Where
- South Korea
- Volunteers
- 221 people
- Sponsor
- Addpharma Inc.